Compare AMTB & VTYX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | AMTB | VTYX |
|---|---|---|
| Founded | 1979 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Medicinal Chemicals and Botanical Products |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 776.2M | 713.6M |
| IPO Year | N/A | 2021 |
| Metric | AMTB | VTYX |
|---|---|---|
| Price | $20.41 | $8.23 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 5 |
| Target Price | ★ $21.75 | $14.60 |
| AVG Volume (30 Days) | 239.0K | ★ 1.4M |
| Earning Date | 01-21-2026 | 11-06-2025 |
| Dividend Yield | ★ 1.75% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 1.59 | N/A |
| Revenue | ★ $388,504,000.00 | N/A |
| Revenue This Year | $61.42 | N/A |
| Revenue Next Year | $2.10 | N/A |
| P/E Ratio | $12.90 | ★ N/A |
| Revenue Growth | ★ 51.98 | N/A |
| 52 Week Low | $15.62 | $0.78 |
| 52 Week High | $24.40 | $10.55 |
| Indicator | AMTB | VTYX |
|---|---|---|
| Relative Strength Index (RSI) | 60.61 | 46.58 |
| Support Level | $19.27 | $8.61 |
| Resistance Level | $20.78 | $9.30 |
| Average True Range (ATR) | 0.43 | 0.64 |
| MACD | -0.08 | -0.10 |
| Stochastic Oscillator | 72.47 | 46.94 |
Amerant Bancorp Inc is a bank holding company. Through its bank, it provides individuals and businesses deposit, credit, investment, wealth management, and fiduciary services, both in the United States and to select international customers. The bank also provides banking services through traditional channels, such as banking centers and ATMs, as well as via secure websites, mobile devices and telephones.
Ventyx Biosciences Inc is a clinical-stage biopharmaceutical company focused on advancing new therapies for millions of patients living with inflammatory diseases and autoimmune, and neurodegenerative disorders. The company is developing a pipeline of novel small-molecule product candidates to address a range of inflammatory diseases. Its product candidate VTX958 is an oral, selective clinical-stage tyrosine kinase type 2 (TYK2) inhibitor designed to inhibit TYK2 without detectable inhibition of other Janus kinase (JAK) isoforms, which avoids toxicities associated with broader JAK inhibition and, thus, other JAK inhibitors.